Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.43 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13120575 | 0.91 | GSK3B (0.70) | GSK3BCDK2 | |
| SCHEMBL13289368 | 0.89 | GSK3B (0.56) | GSK3BCHEK1CDK2 | |
| SCHEMBL13289405 | 0.89 | GSK3B (0.57) | GSK3BCHEK1CDK2 | |
| SCHEMBL13289096 | 0.89 | GSK3B (0.55) | GSK3BCHEK1LMNACDK2CYP3A4 | |
| SCHEMBL13289011 | 0.88 | GSK3B (0.56) | GSK3BCHEK1CDK2 | |
| SCHEMBL13289388 | 0.88 | GSK3B (0.56) | GSK3BCHEK1CDK2 | |
| SCHEMBL13289362 | 0.88 | GSK3B (0.61) | GSK3BCHEK1CDK2CYP2C9CYP2C19 | |
| SCHEMBL13305374 | 0.88 | GSK3B (0.61) | GSK3BCHEK1CDK2 | |
| SCHEMBL13289097 | 0.87 | GSK3B (0.59) | GSK3BCHEK1LMNAPKMCDK2 | |
| SCHEMBL14545841 | 0.87 | GSK3B (0.56) | GSK3BCHEK1LMNACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |